← Back to Clinical Trials
Recruiting NCT05725096

NCT05725096 Role of Coronary CTA on Lipid Management and Risk Factors Control in an Asymptomatic Chinese Population

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05725096
Status Recruiting
Phase
Sponsor Zhang longjiang,MD
Condition Statin
Study Type INTERVENTIONAL
Enrollment 3,400 participants
Start Date 2023-06-28
Primary Completion 2025-03

Trial Parameters

Condition Statin
Sponsor Zhang longjiang,MD
Study Type INTERVENTIONAL
Phase N/A
Enrollment 3,400
Sex ALL
Min Age 40 Years
Max Age 69 Years
Start Date 2023-06-28
Completion 2025-03
Interventions
Coronary Computed Tomography AngiographyTraditional cardiovascular risk stratification

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The primary objective of this study is to determine whether coronary computed tomography angiography (CCTA) -based coronary heart disease(CHD) prevention strategy improves lipid-lowering treatment and cardiovascular risk factor control compared with traditional CHD prevention strategy, guided by a cardiovascular risk score.

Eligibility Criteria

Inclusion Criteria: 1. Nanjing residents who have no plans to leave in the next 5 years 2. Aged from 40 to 69 years 3. Free of any known clinically cardiovascular disease Able to comprehend and sign an informed consent form Exclusion Criteria: 1. Serious liver dysfunction, defined as AST or ALT \> 3 times the normal upper limit 2. Chronic kidney disease (CKD) \> stage 4, defined as eGFR \< 30 ml/min/1.73 m2 3. Prior CCTA or invasive coronary angiography within the last 5 years 4. Any contraindications for CCTA 5. Previous use of statin or non-statin lipid-lowering medication (such as ezetimibe, PCSK9 inhibitor and XueZhiKang) 6. Life expectancy \< 3 years 7. Other reasons the researcher deems inappropriate to attend

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology